Mandate

Vinge advises GTCR in relation to the recommended public offer to the shareholders in Cision

February 14, 2014

Vinge advises Blue Canyon Holdings AB, controlled by GTCR Investment X AIV Ltd., in relation to the public offer to the shareholders in Cision AB (publ). The shares in Cision are admitted to trading on NASDAQ OMX Stockholm. The Board of Directors of Cision recommends Cision’s shareholders to accept the Offer, and the four largest shareholders, representing 43.3 per cent of the shares, have undertaken to accept the offer. GTCR offers SEK 52 in cash per share and the total offer value for all shares in Cision amounts to approximately SEK 775 million.

Cision is a leading provider of cloud-based PR software, services and tools for the media, marketing and public relations industries. Founded in 1980, GTCR is a leading US-based private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare, and Information Services & Technology Industries. Since its inception, GTCR has invested more than USD 10 billion in over 200 companies.

Peter Bäärnhielm, Dain Nevonen and Jo-Anna Nordström assist in connection with the offer. Joacim Rydergård and others assist in connection with due diligence. Mikael Ståhl and Albert Wållgren advise on financing issues. Christina Kokko is client responsible partner. 

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025